INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Dec 16, 2016 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 146,815 | -- | 146,815 |
Dec 16, 2016 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 146,815 | -- | 146,815 |
Dec 16, 2015 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 146,815 | -- | 146,815 |
Mar 09, 2020 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | -- | -- |
Mar 09, 2020 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | $30.63 | 713,990 |
Dec 12, 2019 |
Director, President and CSO
Trans History: 673
|
Director, President and CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | $21.25 | 521,876 |
Dec 12, 2019 |
Director, President and CSO
Trans History: 673
|
Director, President and CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | -- | -- |
Dec 13, 2018 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | $16.80 | 150,000 |
Dec 13, 2018 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | -- | 94,048 |
Dec 13, 2013 |
Director, Pres Regeneron Labs
Trans History: 673
|
Director, Pres Regeneron Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 150,000 | -- | 246,736 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.